Mesmerise to collaborate with Mayo Clinic to Transform Medical Education and Healthcare Workforce Training
Mesmerise is proud to announce the creation of NeuRealities, Inc., a transformative company designed to revolutionize medical education and healthcare training. As part of a know-how agreement with Mayo Clinic, the new company seeks to leverage Mayo Clinic’s unparalleled clinical expertise and trusted knowledge with Mesmerise’s pioneering advancements in AI-powered spatial computing to set a new standard for excellence in immersive learning experiences.
NeuRealities aims to introduce an open-standards digital platform that redefines how healthcare professionals learn and train. By integrating hyper-realistic AI-enabled digital humans, adaptive immersive experiences, and dynamic content tailored to individual learners, the platform can address critical gaps in medical education. Its first initiative—CT training for radiologic technicians—delivers interactive, hands-on scenarios that simplify complex medical concepts, allowing the potential for training to be more efficient, accessible, and effective.
Built on an exclusive worldwide agreement, NeuRealities enables access to Mayo Clinic’s expertise, allowing the intelligent platform to scale trusted expertise and human potential to reach learners worldwide. This commitment to democratizing access to trusted medical education fosters a new era of personalized learning, empowering healthcare professionals to meet the demands of an evolving industry with confidence and competence.
NeuRealities exemplifies a vision to create pioneering digital experiences that break traditional patterns of knowledge delivery, offering scalable, transformative solutions for reimagining healthcare education. This collaborative venture paves the way for a future where trusted expertise is available to anyone, anywhere, empowering healthcare professionals to deliver excellence in care and innovation across the globe.
About The Mesmerise Group
Since 2016, The Mesmerise Group has partnered with Fortune 500 companies to deliver transformative brand experiences, training sessions, and events designed to empower the enterprise. The company was founded by Daglar Cizmeci and Andrew Hawken, who are recognized experts in AI and spatial computing technologies. Their mission is to unlock the potential of these technologies and manage the opportunities and risks they present. The Mesmerise Group is a global company headquartered in London with locations throughout the U.S.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113104722/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management Raises €30 Billion for European Direct Lending Strategy14.1.2025 14:15:00 CET | Press release
Ares Capital Europe VI Final Close Exceeds Target and Hits Hard Cap, Creating the Largest Institutional Fund in the Global Direct Lending Market Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, announced today the final closing of its sixth commingled European direct lending fund, Ares Capital Europe VI (“ACE VI” or the “Fund”). With total commitments of €17.1 billion, the Fund closed above its €15 billion target and reached its hard cap. Ares believes that ACE VI is the largest institutional fund in the global direct lending market to date based on LP equity commitments. The final Fund size represents an approximate 53% increase in LP commitments relative to its predecessor fund, Ares Capital Europe V, which closed in 2021 at its €11.1 billion hard cap. Including related vehicles and anticipated leverage, the total available capital for the Ares European Direct Lending strategy is expected to be approximately €30 billion. Combined wit
Esmark, Inc. and Esmark Steel Group Reaffirms Support for U.S. Steel Merger by Nippon Steel14.1.2025 14:00:00 CET | Press release
Bouchard: “This merger is a game-changer for the steel industry” Esmark, Inc. and Esmark Steel Group today reaffirmed their support for the proposed merger between U.S. Steel and Nippon Steel and urges the Trump administration to revisit this alliance. The proposed merger is positioned to bring significant benefits to the combined company’s workers, strengthened U.S. national security, as well as bolstering America’s status in the international steel industry. The merger will create a formidable force in the steel industry, capable of competing with global players and addressing the challenges posed by Chinese steel exports. By leveraging Nippon Steel's advanced technology and U.S. Steel's extensive market presence, the combined entity will set new standards for quality in steel production, enabling the combined organization to grow for the benefit of its employees, including its United Steelworkers (USW) union members, and the communities in which it operates. "This merger is a game-c
FiRa Consortium Unveils FiRa Core 3.0 Specifications and Certification Program14.1.2025 14:00:00 CET | Press release
Advancing UWB technology with enhanced scheduling and data transfer The FiRa® Consortium announces the release of its Core 3.0 Specifications and Certification Program, notable milestones in ultra-wideband (UWB) technology development. These updates enhance UWB’s capabilities, enabling seamless interoperability and unlocking new possibilities for precise and secure ranging and positioning in diverse applications. Features of the FiRa Core 3.0 Specifications and Certification Program FiRa is introducing three major UWB features in its Core 3.0 Specifications. Advancements designed to enhance the efficiency and versatility of UWB systems include: Hybrid UWB Scheduling (HUS): This feature – detailed in the FiRa MAC and FiRa UCI Technical Specifications – enables advanced UWB applications that require various combinations of FiRa features to work together deterministically, ensuring optimized performance in complex environments such as public transport systems. Dedicated Data Transfer: Des
ACE Fiber drives high-speed connectivity to New Albany with Adtran broadband solution14.1.2025 14:00:00 CET | Press release
News summary: Building on its success in Alcorn County, the nation’s first electric co-op is extending its all-Adtran network to more Mississippi communities ACE Fiber is now connected to New Albany with FSP 3000 open optical transport technology and ALM in-service fiber monitoring Adtran’s access solution enhanced by Mosaic One SaaS delivers superior management, scalability and customer experience Adtran today announced the expansion of Alcorn County Electric Power Association’s (ACE Power) fiber subsidiary, ACE Fiber, into New Albany, Mississippi. The new network utilizes Adtran’s comprehensive suite of fiber network technologies, significantly enhancing internet speed, accessibility and reliability for homes and businesses throughout the city. The deployment features Adtran’s FSP 3000 open optical transport solution and real-time fiber assurance from the ALM monitoring platform. Adtran’s multigigabit fiber-to-the-home technology, optimized by Mosaic One SaaS, ensures superior networ
Swiss-based Non-profit GARDP Supports the Development of Debiopharm’s New Potential Treatment for Gonorrhoea14.1.2025 14:00:00 CET | Press release
The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae. Multidrug-resistant strains of N. gonorrhoeae have emerged globally, limiting treatment options and elevating this pathogen to the high-priority category on the World Health Organization’s Bacterial Priority Pathogen List. Such pathogens present distinct public health challenges that urgently require new treatments. “Antibiotic-resistant gonorrhoea represents a serious threat to sexual and reproductive health,” said Morgane Vanbiervliet, Manager of Market Intelligence & Business Development, Infectious Diseases, Debiopharm. “Debio 1453 shows encouraging pre-clinical efficacy against resistant strains of N. gonorrhoeae. We are eager to continue to develop this compound in collaboration with GARDP.” Debiopharm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom